Contributions
Abstract: P865
Type: Poster
Abstract Category: Clinical aspects of MS - 4 Natural course
Background: Benign multiple sclerosis (MS) is a controversial concept due to the fact that some of the patients that fulfill this definition will eventually develop disability. The aim of this study is to evaluate the percentage of patients with benign forms of MS (defined as EDSS≤3 after one decade of disease duration) and to determine whether this situation is stable after 20 and after 30 years.
Methods: Patients were selected from a hospital-based series of 485 multiple sclerosis patients assessed in 1996 and were prospectively registered using the European Database for Multiple Sclerosis (EDMUS) and followed up on a 6-monthly basis and at the time of relapse. Those who met the following criteria were selected: clinically definite MS according to the Poser criteria, relapsing remitting form and fulfilling the definition of benign MS: EDSS ≤3 after 10 years of disease evolution.
Results: 82 from 485 patients evaluated in 1996 fulfilled the inclusion criteria and were selected for the study (63.4% female; mean age at onset 24.9 years, SD 9.7). 67 out of 82 patients could be assessed in 2006 and 53 in 2016. In 51 (76.1%) patients evaluated in 2006 and in 31 (58.5%) in 2016, the EDSS persisted at ≤3. Other EDSS steps were evaluated as possible predictors of benign outcome after 20 years. The EDSS≤2 after 10 years of MS duration provides an 85.4% of probabilities of remaining in the benign group (EDSS≤3) after 20 years and a 65% after 30 years from onset.
Conclusion: In our series, every 10 years of MS evolution, a reduction of almost 20% of patients with benign MS is detected.
Disclosure: E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
MA Mañé-Martínez received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
M. Jato reports no disclosure
S. Martínez Yélamos received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
Abstract: P865
Type: Poster
Abstract Category: Clinical aspects of MS - 4 Natural course
Background: Benign multiple sclerosis (MS) is a controversial concept due to the fact that some of the patients that fulfill this definition will eventually develop disability. The aim of this study is to evaluate the percentage of patients with benign forms of MS (defined as EDSS≤3 after one decade of disease duration) and to determine whether this situation is stable after 20 and after 30 years.
Methods: Patients were selected from a hospital-based series of 485 multiple sclerosis patients assessed in 1996 and were prospectively registered using the European Database for Multiple Sclerosis (EDMUS) and followed up on a 6-monthly basis and at the time of relapse. Those who met the following criteria were selected: clinically definite MS according to the Poser criteria, relapsing remitting form and fulfilling the definition of benign MS: EDSS ≤3 after 10 years of disease evolution.
Results: 82 from 485 patients evaluated in 1996 fulfilled the inclusion criteria and were selected for the study (63.4% female; mean age at onset 24.9 years, SD 9.7). 67 out of 82 patients could be assessed in 2006 and 53 in 2016. In 51 (76.1%) patients evaluated in 2006 and in 31 (58.5%) in 2016, the EDSS persisted at ≤3. Other EDSS steps were evaluated as possible predictors of benign outcome after 20 years. The EDSS≤2 after 10 years of MS duration provides an 85.4% of probabilities of remaining in the benign group (EDSS≤3) after 20 years and a 65% after 30 years from onset.
Conclusion: In our series, every 10 years of MS evolution, a reduction of almost 20% of patients with benign MS is detected.
Disclosure: E.Matas received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Bau received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
L.Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
MA Mañé-Martínez received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
M. Jato reports no disclosure
S. Martínez Yélamos received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.